| Bioactivity | Gosuranemab (BMS-986168) is a humanised IgG4 anti-tau monoclonal antibody. Gosuranemab binds to human N-terminal tau residues 15-22. Gosuranemab has the potential for the research of alzheimer’s disease (AD)[1][2]. |
| Name | Gosuranemab |
| CAS | 1788032-39-2 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Song C, et al. Immunotherapy for Alzheimer's disease: targeting β-amyloid and beyond. Transl Neurodegener. 2022 Mar 18;11(1):18. [2]. Imbimbo BP, et al. A critical appraisal of tau-targeting therapies for primary and secondary tauopathies. Alzheimers Dement. 2022 May;18(5):1008-1037. |